Introduction: This study aimed to evaluate the long-term efficacy of multimodality therapy for patients with type B3 thymoma. Methods: A total of 188 consecutive patients with type B3 were treated in our hospital from January 2001 to December 2010. One hundred seventy-seven patients who had been treated with curative intent were retrospectively analyzed. According to World Health Organization Classification, all patients were pathologically confirmed as type B3. Distribution of Masaoka stages I, II, III, and IV was 35 (19.8%), 20(11.3%), 78 (44.1%), and 44 (24.8%), respectively. Myasthenia gravis coexisted in 34% of patients. Results: After a mean follow-up of 49 months (7-135 months), the 10-year overall survival (OS) rates were 65% (89%, 86%, 61%, and 42% in stage I, II, III, and IV, respectively). One hundred five patients patients (102 patients with R0 resection and 3 with complete response after radiotherapy) were analyzed for freedom from recurrence (FFR). The 5-and 10-year FFR rates were 91% and 73% (100%, 94%, 84%, 71% and 100%, 94%, 56%, N/A in stages I, II, III, and IV, respectively. We have no data of stage IV.) TTP was calculated on 72 patients including 57 patients with R+ resection and 15 with partial response or stable disease after radiotherapy. The 5-year time-to-progression (TTP) rates were 33% (41%, 24% in stage III and IV, respectively). Multivariate analysis showed that prognostic factors for OS were the Masaoka stage and adjuvant radiation for patients with stage III and IV. The Masaoka stage and resection margin after surgery had significant effects on FFR and TTP. Conclusion: The type B3 thymoma often presented with the later stages at the diagnosis. The Masaoka stage was closely associated with OS, FFR, and TTP. Resection margin after surgery was related to TTP. Adjuvant radiotherapy may be beneficial to stage III and IV patients in this clinical setting.
T hymomas are unusual, low-grade malignant tumors of the thymic epithelium and the most common tumors of the anterior mediastinum with a low incidence of 2.5 to 3.2 per 1,000,000 persons. 1, 2 The World Health Organization (WHO) classification 3, 4 is a systematic histologic classification and has been proved to be useful in distinguishing different clinical characteristics of patients of a particular subtype from others and has independent prognostic value. The proportion of B3 types reported went from 6% to 34%, and has been shown to be the worst prognosis (average 63 ± 19% of 10-year survival), compared with other subtype thymoma.This is because type B3 has shown more malignant behavior in terms of postoperative survival, tumor recurrence, and local invasiveness. 5, 6 It has been reported that patients with type B3 have the risk of invasiveness ranging from less than 40% to almost 90%. 6, 7 The propensity of invasion to neighboring tissues, as reflected by the Masaoka clinicopathologic staging system, negatively affects prognosis of patients with type B3. 8 There are no consensus guidelines for the treatment of type B3 thymoma. Although radical surgical resection remains the primary approach for the patients, the efficacy of adjuvant or neoadjuvant therapies is still controversial because of the lack of the confirmation of randomized trials. This retrospective study is the first to evaluate the long-term efficacy of multimodality therapy for patients with a large cohorts of type B3 thymoma patients.
PATIENTS AND METHODS

Patient's Characteristics
From January 2001 to December 2010, 188 consecutive patients with type B3 thymoma were treated in Shanghai Chest Hospital of Jiaotong University, China. One patient died of myasthenia gravis (MG) half a month after surgery, 10 patients were lost at follow-up after the surgery. All patients had been pathologically confirmed as type B3 thymoma (WHO histologic classification) by surgery or needle biopsy, and most patients were treated by a combination of surgery and neoadjuvant or adjuvant therapy. Data from 177 patients were reviewed retrospectively.
Treatment Surgery
One hundred fifty-nine of 177 patients with stage I-IVa had undergone radical thymectomy, defined as the resection of the entire thymus and mediastinal fat tissue between both phrenic nerves. Surgical access through the median sternotomy was completed in 92 patients, thoracotomy in 53 patients, and video-assisted thoracoscopy in 14 patients. Biopsy or debulking was performed in 18 of 177 patients with stage III (3), IVa (2), and IVb (13) . Thymoma was staged according to the Masaoka system.
External radiotherapy
There are neither consensus statements nor randomized trial data for analysis regarding the use of adjuvant radiation therapy, so the external beam radiotherapy (EBRT) was offered to the patients either with advanced stage, who received non-extirpative surgery or were recommended by surgeon. One hundred twenty-six of 177 patients (71%) received adjuvant EBRT (113 patients), neoadjuvant EBRT (5 patients) for resectable patients, or palliative EBRT (8 patients) for nonsurgery patients. The EBRT techniques are described as the following: based on a preoperative computed tomography (CT) scan and surgical clips, the entire tumor bed and part of the involved adjacent organ with at least a 1.5-cm margin, when there was parenchymal involvement or as delineated by surgical clips, were included in the radiation field. Treatment was delivered with 6 MV photons using multifield techniques (anteroposterior/posteroanterior, with 1-2 lateral fields) depending on dose coverage and the volume of organ at risk. A three-dimensional dose calculation was done during the treatment planning. The median doses was 49 Gy (range, 36-66Gy), Additional 6 to 10 Gy was given to the tumor as a boost if R2 had been defined for the resectable patients.
Chemotherapy
There is scant information about chemotherapy in type B3 thymoma. We did not develop a systematic chemotherapy procedure. Chemotherapy were offered for some of the patients in advaced stage and who received palliative resection. Neoadjuvant chemotherapy was used in six patients (3%) who received two cycles of chemotherapy, another 29 patients (16%) received four cycles of adjuvant chemotherapy. The chemotherapy drugs involved were infosfamide, cyclophosphamide, cisplatinum, docetaxol fluorouracil, among others.
Follow-Up and Statistical Analysis
Patients were followed up according to protocol every 3 months after the completion of treatment in the initial 2 years, then every 6 months thereafter. Follow-up examinations included complete history, physical examinations, complete blood count, serum chemistry, ultrasound of liver, CT of the chest and abdomen or earlier, if recurrence was suspected. The definition of recurrence was based on the standard of the International Thymic Malignancy Interest Group. 9 The duration of overall survival (OS) was calculated from the date of operation until death or the date of the last follow-up. Freedom from recurrence (FFR) was measured from the date of operation until the date of recurrence for patients who had no evidence of disease (i.e., an R0 resection or radiographic complete response) after a curative-intent treatment). Time to progress (TTP) was measured for patients in whom all disease was not eradicated (i.e., R1 or R2 resection, radiographic stable disease [SD] , or partial response [PR] ). The Kaplan-Meier method was used to estimate the OS, FFR, and TTP for the entire cohort and to perform univariate analysis for the assessment of prognostic factors. The comparisons were tested using the log-rank test. Multivariate analysis was performed using the Cox regression model. Statistical analysis was performed using SPSS software version 12.0 (SPSS, Chicago, IL).
RESULTS
Treatment Outcome
Patients' characteristics are detailed in Table 1 . The median follow-up for all patients was 46 months (range, 15-135 months). The median survival time was 49 months (range, 7-135 months) for the entire group of patients. Of the 177 patients, 102 underwent an R0 resection, 57 underwent R1 or R2 resection, 18 received biopsy or debulking, of which three patients achieved CR after curative radiotherapy. At the time of the analysis, 39 patients (22%) had disease recurrence and 19 patients (12%) were deceased. The 5-and 10-year OS rates were 84%, 65% (100%, 89%, 86%, 60% and 89%, 86%, 61%, 42% in stage I, II, III, and IV, respectively). One hundred five patients (102 patients with R0 resection and 3 patients with CR after radiotherapy) were analyzed for FFR. The 5-, 10-year FFR rates for the patients after R0 resection were 91% and 73% (100%, 94%, 84%, 71% and 100%, 94%, 56%, N/S) in stage I, II, III and IV, respectively). TTP was calculated on 72 patients including 57 patients with R+ resection and 15 patients with PR or SD after radiotherapy. The 5-year TTP rates for the patients who had disease after treatment (i.e., R1, R2 resection; radiographic SD or PR after treatment) were 33% (41% for R1, 24% for R2), respectively (Fig. 1) .
Site of Recurrences
Recurrences developed in 39 patients (22%). Eight of 39 patients had tumor bed recurrence, and pleural relapse was the most common site (35 of 39 patients). For 105 patients with either R0 resection or CR after radiotherapy, 14 of them had developed recurrence and 12 had pleural relapse. Thirteen patients (7%) had distant metastasis. The sites of distant metastasis were lung (3%), lymph nodes (2%), brain (1%), liver (2%), and bone (2%), respectively. There were four patients who developed both local and distant metastasis.
Prognostic Factors for OS, TTP, and FFR
All 177 patients treated with curative intent were analyzed for the prognostic factors of OS. One hundred five of them who were successfully treated patients (R0/CR) were used for the analysis of FFR, and 57 patients who were unsuccessfully treated patients (R1, 2/PR, SD) were used for the analysis of TTP. The impact of age, sex, MG, tumor size, Masaoka stage, resection margin, surgery approach, and adjuvant radiation on OS, FFR, and TTP were studied in both uni-and multivariate analyses ( Table 2 ). In the univariate analysis, the Masaoka stage was significantly associated with OS, FFR, and TTP (p < 0.05). Tumor size and adjuvant radiation for either all of patients or the patients with stages III to IV were the predictors of OS (p < 0.05). Chemotherapy was significantly associated with TTP (p < 0.05). Multivariate analysis revealed that the Masaoka stage and adjuvant radiation for patients with stage III to IV were independent prognostic factors for OS (p < 0.05) (Fig. 2) . The positive resection margin negatively impacted on TTP (p = 0.03).
DISCUSSION
The prognostic value and clinical applicability of WHO classification systems have been confirmed in two other metaanalysis studies. 5, 10 In this study, however, we are the first to analyze a large cohort of primary thymomas with particular emphasis on patients with type B3. One hundred seventyseven patients were retrospectively reviewed and were studied to elucidate and specify the factors predicting prognosis of thymoma after multimodal treatment.
Factors involving the prognosis of thymoma remain under discussion because of its rarity and indolent natural history. It is generally accepted that surgery is the mainstay treatment, and clear resection is one of the most independent prognostic factors for thymoma. 11 In our series, 90% patients underwent extended thymectomy through different surgical accesses but with curative resection, the resectability had not negatively been impacted by the choice of surgical accesses and had not been associated with the prognosis of patients. However, the proportion of the complete resection could be significantly lower in patients affected by type B3 than in patients affected by other types reported, because type B3 closely correlated with the percentage of the invasive tumors, so that incomplete resection affected the prognostic value of type B3 histology. Our data confirmed that 122 of 177 patients (69%) had invasive disease and all patients with incomplete resection had stage III and IV and had micro-or macroscopic invasion into surrounding structures such as the pleura, pericardium, and great vessels before surgery. Incomplete resection had a significantly negative impact on TTP of type B3 in both uni-and multivariate analyses in our study.
Large tumors (>8 cm in diameter) have been reported as a worse prognosis because they intuitively correlated with degree of invasion. 13, 14 Our data showed that 106 of 177 patients (60%) had tumor size greater than 6 cm in diameter and 85 of them (80%) had staged as III or IV, indicating that there was a correlation with tumor invasion (data not shown). Tumor size was a worse predictor of the OS in the univariate analysis in the current study, but failed to correlate with OS, FFR, and TTP of type B3 thymoma patients in multivariate analysis; this could be explained by the fact that tumor extent, as proposed in the Masaoka staging system, is more relevant than tumor dimension. 15 However, the Masaoka stage is very difficult to be assigned before resection because invasion is difficult to differentiate from simple abutment on the CT scan. Tumor size may be useful for the decision making of therapeutic choice before resection because neoadjuvant therapy might have better survival advantages than that adjuvant therapy for late advanced thymomas. 16 It remains controversial whether MG is one of the prognostic factors for thymoma. Some studies have shown that the association with MG was one of the risk factors for OS in multivariate analysis, 17 but other recent studies reported that MG does not influence the survival or is even associated with better prognosis because symptoms of MG might lead to early diagnosis. [18] [19] [20] The incidence of MG in thymoma is relatively low in A and C subtypes compared with B subtype, and varies from 25% to 65% for type B3 in most reports. 10, 21 In our study, 30.5% of type B3 patients had accompanied with MG. Both uni-and multivariate analyses have not shown that MG was associated with 10-year OS, FFR, and TTP. Therefore, it is necessary to further clarify whether MG would influence the prognosis of type B3 thymoma.
In past literature, 7 the Masaoka staging system has been shown to be an independent prognostic factor in all subtype thymomas. Our present study demonstrated that the Masaoka stage was an independent prognostic factor for type B3 thymoma in both uni-and multivariate analyses. There were significant differences among stage I/II versus III versus IVa in terms of OS and FFR (p = 0.04, p = 0.01, respectively). Type B3 is of more aggressive nature than other subtypes, around 60% to 90% of patients were staged as III or IV at the first diagnosis as reported. 22 One hundred twenty-two of 177 patients (68.9%) in our study had invasive disease and were at Masaoka III or IV. B3 thymomas are more aggressive than other thymomas, 23 and 5-year survival rate was around 50% (stage III-IV). 24 Therefore, multimodality therapies including neoadjuvant chemotherapy, surgery, adjuvant chemotherapy, and radiotherapy warrant further study for this particular population of patients.
Evaluation of the role of radiation therapy in the management of malignant thymoma, or patients with incomplete resection, and as such, adjuvant radiotherapy, could maximize local control, even improve survival. 24 ,25 Adjuvant radiotherapy is not usually recommended after a totally resected stage I thymoma. Although the incidence of intrathoracic recurrence for patients with stage II and III has been about 28% to 40% after surgery alone, 24, 26 there was some controversy about the positive effects of the addition of postoperative radiotherapy, especially for patients with stage II and III after complete resection. 27, 28 In our study, adjuvant radiotherapy had no impact on the OS, FFR, and TTP in multivariate analyses. Although the patients were stratified based on Masaoka stage, adjuvant radiotherapy improved the OS for stage III to IV patients in multivariate analyses.
Postoperative mediastinal irradiation was usually used to prevent local recurrence, but it was unable to prevent regional recurrence like pleural dissemination. As we observed in our study, 35 of 43 locally recurrent patients presented with pleural site, and this may compromise the efficacy of adjuvant radiotherapy for the local control. Therefore, some authors have advocated the adoption of prophylactic radiotherapy to the entire hemithorax against pleural dissemination and achieved a better 5-year relapse-free rate when compared with those obtained by mediastinal irradiation alone. 29, 30 Because most treatment recommendations have been based on retrospective data, the role of adjuvant radiotherapy has to be further clarified in more randomized studies.
To our knowledge, we report the largest series of type B3 thymoma managed with radical surgery and combined with or without adjuvant therapy. However, we consider our results far from conclusive, and several important issues need to be addressed. First, the patients' treatment was not arranged according to a prospective institutional treatment protocol, it was certainly a substantial pitfall in our study. In addition, our study was a retrospective analysis and most of patients received adjuvant therapy, hence the number of patients required for a set level of statistical power may not have been enough to determine the role of adjuvant therapy. Finally, although the mathematical model of statistical analysis package could take the short follow-up time of some patients into consideration, the conclusions may still be biased and have to be interpreted with caution. All these issues need to be further addressed in future prospective clinical trials.
In conclusion, we retrospectively reviewed the outcome of type B3 thymoma with the largest cohorts of patients as reported. Our data showed that type B3 was in a more advanced stage at the first diagnosis. Surgery remains the mainstay treatment and the residual status after surgery was an independent prognostic factor, in addition to the Masaoka stages and adjuvant radiotherapy for stage III to IV patients. Given the nature of retrospective analysis, our results should be confirmed by further prospective studies.
